Skip to content Skip to main navigation

Health Canada approves ruxolitinib for PV patients

Published February 19, 2016.

Health Canada has approved ruxolitinib (Jakavi®) for the control of hematocrit in adult patients with polycythemia vera (PV) who are resistant to or intolerant of a cytoreductive agent.

Read Novartis press release

Stay up to date

Read the Canadian MPN Group newsletter for the latest in the field.

Watch Dr Vikas Gupta speak about Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era.

Download the new MPN eSimple app.

We need your help

The Canadian MPN Group relies on donor contributions to keep our work going. Can you help?

Twitter Feed